Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

Esbriet as follows: Germany in September of 2011; France, Spain and Italy during the first half of 2012 and the United Kingdom by mid-2012.  InterMune plans to have a focused organization in Europe of approximately 125 full-time personnel by the end of 2012, supported by expert consultants and third-party service providers.  InterMune will provide an update at the meeting and on the webcast on the company's launch preparations for Esbriet in Europe.

ASCEND: New Phase 3 Trial

During the meeting, Bill Bradford, Senior Vice President of Clinical Science and Biometrics, will provide an update on InterMune's new Phase 3 study named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF). ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

ASCEND will be a randomized, 52-week placebo-controlled trial with a primary endpoint of change in forced vital capacity (FVC), a key measure of lung function, between baseline and Week 52. The trial will enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function who will be randomly assigned to receive oral pirfenidone (2403 mg/day) or placebo. More details will be provided at the meeting and on the webcast.

Primary enrollment will take place in the U.S. with additional centers in Mexico, South America, Australia and New Zealand, across more than 140 investigational sites in total. InterMune expects to begin enrollment in ASCEND in June 2011, with all trial participants fully enrolled by the first half of 2012.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Guidance for 2011 Expenses

InterMune also will discuss at the Analyst Day its 2011 financial guidance for operating expenses.  The company today provided its forward-looking expense guidance fo
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... DUBLIN , Sept. 23, 2014 /PRNewswire/ ... "Company"), a biotechnology company pioneering the manufacturing and ... emerging nations, today announced that the Depository Trust ... DTC,s Deposit and Withdrawal at Custodian ("DWAC") service ... transfer agent as the distribution point.  The Company,s ...
(Date:9/23/2014)... -- This test can detect HIV infection if used 3 ... activities that can transfer body fluids from one person to ... needles. , An in-vitro diagnostic home-use test for ... works by looking for your body,s response to fighting the ... patients to learn their status in a single visit and ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
Breaking Medicine Technology:TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5
... N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox,Pharmaceutical Corporation ... the Company's recently completed studies of,NX-1207 for ... at,a series of upcoming U.S. urology meetings, ... Urological Association Meeting in,Colorado Springs. These independent ...
... June 21, 2007 /PRNewswire/ -- , What and When , Data ... presented in poster format at the 67th,Scientific Sessions of the American ... serious adverse events in high-risk type 2, ... from, PROactive; Poster 0553-P presented ...
Cached Medicine Technology:Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 3
(Date:9/23/2014)... Doheny HealthDay Reporter TUESDAY, ... very low birth weights, breast milk is more likely than ... known as cytomegalovirus (CMV), a new study finds. The ... -- all of whom weighed 3.3 pounds or less and ... CMV infection, to see whether breast milk or transfusions carried ...
(Date:9/23/2014)... drinking and getting drunk at an early age are ... students, a new study suggests. The conclusions, based ... could help expand alcohol-prevention efforts aimed at teens to ... becoming binge drinkers, the researchers suggested. , , "Efforts ... progression to first heavy use as risk factors for ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- Few children ... undergo behavioral therapy, and the rates vary six-fold ... study finds. Medication alone can manage symptoms ... better if they also receive behavioral therapy (psychotherapy), ... analyzed data in more than 1,500 counties across ...
(Date:9/23/2014)... grow up to earn up to 18 percent less ... Lundborg of Lund University, Paul Nystedt of Jnkping University ... all in Sweden. The team compared extensive information from ... the results are published in Springer,s journal Demography ... 145,193 Swedish-born brothers who enlisted in the Swedish National ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Note to young men: Fat doesn't pay 2
... evidence of the damaging impact of marijuana on humans ... symptoms in some people, including hallucinations and paranoid delusions, ... recent study, one compound, cannabidiol, or CBD, made people ... tetrahydrocannabinol, or THC, produced temporary psychotic symptoms in people, ...
... victims of a bite from the Brazilian wandering spider (Phoneutria ... in blood pressure, they also sport an uncomfortable erection. ,And ... Viagras. Scientists say they have figured out the chemical that ... , “The erection is a side effect that everybody who ...
... healthcare scheme proposed by the Australian Federal government. The ... people to opt for private health insurance; yet this plan ... by public hospital, a report has shown. ,Dr ... Research on Health, explained the benefits of doing away with ...
... affect people of all ages. The general public is at ... instruction on ladder use and safety. ,According to ... Journal of Preventive Medicine and conducted by the Center for ... than 2.1 million individuals were treated in U.S. emergency departments ...
... suffer migraine attacks, beware. Recent research has shown the ... depression and suicidal tendencies. They could also be suffering ... ,Teens suffering migraines are prone to depressive tendencies ... such agonizing headaches, a new study has shown. ...
... homes have started coming to the fore. One among fifty ... review by the Department of Ageing, Disability and Home Care, ... involving abuse and lack of care. The main cause was ... carers. ,Advocates nationwide say it is a growing problem ...
Cached Medicine News:Health News:Marijuana can Trigger Psychotic Symptoms, New Study Finds 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2Health News:$3bn Rebate Scheme – Is Australia Making a Prudent Move 2Health News:Ladder-related Injuries on the Rise in U.S 2Health News:Link Between Migraine Attacks in Teens and Suicidal Tendencies 2Health News:Abuse of the Disabled in Government Run Homes 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The Research Family includes fixed-volume, ... as the electronic Eppendorf Research pro ... button, these compact, high-performance pipettes have ... Optimally suited for use with original ...
10L...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Medicine Products: